Aptar Q1 Revenue $982.9M Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Reports Q1 revenue $982.9M, consensus $955.9M. "Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP-1 therapies, biologics, systemic nasal drug delivery, nasal decongestants, ophthalmic dispensing, and active material solutions. As anticipated, first quarter results were impacted by emergency medicine destocking, with comparisons further challenged by the exceptionally strong prior-year quarter for the prescription division. The injectables division delivered another quarter of strong, double-digit growth. Consumer dispensing also contributed positively, with volume growth across Beauty and Closures, supported by robust demand in prestige fragrance and beverage applications," said Stephan B. Tanda, Aptar President and CEO.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 115.510
Low
133.00
Averages
145.33
High
156.00
Current: 115.510
Low
133.00
Averages
145.33
High
156.00
About ATR
AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aptar and Clarins Win 2026 DIELINE Award for Sustainable Design
- Sustainable Design Innovation: The custom reloadable airless packaging solution developed by Aptar and Clarins reduces material impact by 73%, utilizing 50% less metal, 33% less plastic, and 29% less cardboard, significantly enhancing product sustainability and market competitiveness.
- Industry Recognition: The Clarins Total Eye Lift packaging solution received the Formes de Luxe Award in 2025 and was awarded First Place in the Sustainable Design category at the 2026 DIELINE Awards, highlighting its excellence in innovation and execution.
- Technological Advantage: Aptar's patented Gaïa airless technology combines a premium metal outer casing with plastic reloads, preserving luxury aesthetics while significantly reducing material usage, enhancing product circularity and consumer experience.
- Market Impact: This innovation not only elevates Clarins' market differentiation and brand equity but also demonstrates the compatibility of luxury and sustainability, driving progress in the high-end skincare market.
See More
AptarGroup Q1 2026 Earnings Call Insights
- Financial Performance Overview: AptarGroup reported an 11% increase in sales with flat core sales, achieving adjusted EBITDA of $189 million and an EBITDA margin of 19.2%, indicating that overall performance met expectations amid anticipated emergency medicine destocking.
- CEO Transition: Current CEO Stephan Tanda announced his retirement effective September 1, with Gael Touya set to take over, highlighting the company's stability and strategic continuity during leadership changes.
- Market Demand Dynamics: The Pharma segment continues to see growing demand in key areas such as GLP-1, biologics, and systemic nasal drug delivery, with prescription core sales down 10% but injectables core sales up 20%, reflecting a differentiated market trend.
- Future Outlook and Investment: Management guided for second quarter adjusted earnings per share between $1.32 and $1.40, while planning capital investments of $260 million to $280 million, demonstrating the company's confidence in future growth and commitment to ongoing investments.
See More
AptarGroup Reports Decline in Q1 Earnings
- Earnings Decline: AptarGroup's Q1 net income fell to $72.67 million, or $1.12 per share, down from $78.79 million and $1.17 per share last year, indicating profitability challenges for the company.
- Revenue Growth: Despite the earnings drop, the company reported a 10.8% increase in revenue to $982.86 million compared to $887.30 million last year, demonstrating strong sales performance.
- Adjusted Earnings: Excluding special items, AptarGroup's adjusted earnings were $77.20 million, or $1.19 per share, indicating stability in core operations despite the overall earnings decline.
- Future Guidance: The company provided Q2 EPS guidance of $1.32 to $1.40, reflecting management's cautiously optimistic outlook for future performance, which may attract investor interest.
See More
AptarGroup Q1 2026 Earnings Exceed Expectations
- Earnings Beat: AptarGroup reported a Q1 2026 non-GAAP EPS of $1.19, exceeding expectations by $0.04, indicating strong performance and improved profitability in the market.
- Significant Revenue Growth: The company achieved revenues of $982.9 million in Q1, reflecting a 10.8% year-over-year increase and surpassing market expectations by $26.96 million, demonstrating sustained growth in sales and market demand.
- Optimistic Outlook: Aptar anticipates adjusted EPS for Q2 2026 to be in the range of $1.32 to $1.40, reflecting confidence in future performance while assuming an effective tax rate between 22.5% and 24.5%.
- Exchange Rate Consideration: This earnings guidance is based on an exchange rate of 1.18 Euros to USD, highlighting the company's foreign exchange risk management strategy in its global operations.
See More
Aptar Named One of America's Climate Leaders for Fourth Consecutive Year
- Recognition as Climate Leader: AptarGroup has been named one of America's Climate Leaders by USA Today for the fourth consecutive year, reflecting the company's long-term commitment to sustainability and climate action, thereby enhancing its market reputation in environmental stewardship.
- Emission Reduction Achievements: Since its 2019 baseline year, Aptar has achieved significant reductions in Scope 1 and Scope 2 emissions, indicating effective measures in reducing climate impact and further solidifying its leadership position in the industry.
- Science-Based Targets: Aptar's science-based targets align with the goal of limiting global warming to 1.5°C, aiming for reductions in renewable electricity use and Scope 3 emissions by 2030, showcasing its proactive strategies in addressing climate change.
- Global Recognition and Engagement: Aptar has been recognized by CDP with an
See More
Aptar Partners with Enable for enFuse® Digital Health Solution
- Strategic Partnership: Aptar Digital Health has formed a strategic partnership with Enable Injections, becoming the preferred digital health partner for the enFuse® system, aimed at enhancing patient experience and engagement throughout the injection process.
- Digital Solution Features: The new solution will include features such as treatment data recording, onboarding modules, injection guidance, and symptom tracking, empowering patients and caregivers with greater confidence and control over the treatment process, thereby improving adherence.
- Flexible Architecture Design: Built on a flexible and scalable architecture, the solution will be deployed alongside the enFuse® system, supporting pharmaceutical partners across the entire drug development lifecycle from clinical trials to commercialization, enhancing the therapeutic value.
- Data-Driven Decision Making: By capturing adherence data and patient-reported outcomes remotely and providing actionable insights through analytics dashboards, the solution will assist pharmaceutical companies in making more informed decisions in clinical development and market readiness, ultimately improving the patient treatment journey.
See More
Aptar and Clarins Win 2026 DIELINE Award for Sustainable Design
- Sustainable Design Innovation: The custom reloadable airless packaging solution developed by Aptar and Clarins reduces material impact by 73%, utilizing 50% less metal, 33% less plastic, and 29% less cardboard, significantly enhancing product sustainability and market competitiveness.
- Industry Recognition: The Clarins Total Eye Lift packaging solution received the Formes de Luxe Award in 2025 and was awarded First Place in the Sustainable Design category at the 2026 DIELINE Awards, highlighting its excellence in innovation and execution.
- Technological Advantage: Aptar's patented Gaïa airless technology combines a premium metal outer casing with plastic reloads, preserving luxury aesthetics while significantly reducing material usage, enhancing product circularity and consumer experience.
- Market Impact: This innovation not only elevates Clarins' market differentiation and brand equity but also demonstrates the compatibility of luxury and sustainability, driving progress in the high-end skincare market.
See More
AptarGroup Q1 2026 Earnings Call Insights
- Financial Performance Overview: AptarGroup reported an 11% increase in sales with flat core sales, achieving adjusted EBITDA of $189 million and an EBITDA margin of 19.2%, indicating that overall performance met expectations amid anticipated emergency medicine destocking.
- CEO Transition: Current CEO Stephan Tanda announced his retirement effective September 1, with Gael Touya set to take over, highlighting the company's stability and strategic continuity during leadership changes.
- Market Demand Dynamics: The Pharma segment continues to see growing demand in key areas such as GLP-1, biologics, and systemic nasal drug delivery, with prescription core sales down 10% but injectables core sales up 20%, reflecting a differentiated market trend.
- Future Outlook and Investment: Management guided for second quarter adjusted earnings per share between $1.32 and $1.40, while planning capital investments of $260 million to $280 million, demonstrating the company's confidence in future growth and commitment to ongoing investments.
See More
AptarGroup Reports Decline in Q1 Earnings
- Earnings Decline: AptarGroup's Q1 net income fell to $72.67 million, or $1.12 per share, down from $78.79 million and $1.17 per share last year, indicating profitability challenges for the company.
- Revenue Growth: Despite the earnings drop, the company reported a 10.8% increase in revenue to $982.86 million compared to $887.30 million last year, demonstrating strong sales performance.
- Adjusted Earnings: Excluding special items, AptarGroup's adjusted earnings were $77.20 million, or $1.19 per share, indicating stability in core operations despite the overall earnings decline.
- Future Guidance: The company provided Q2 EPS guidance of $1.32 to $1.40, reflecting management's cautiously optimistic outlook for future performance, which may attract investor interest.
See More
AptarGroup Q1 2026 Earnings Exceed Expectations
- Earnings Beat: AptarGroup reported a Q1 2026 non-GAAP EPS of $1.19, exceeding expectations by $0.04, indicating strong performance and improved profitability in the market.
- Significant Revenue Growth: The company achieved revenues of $982.9 million in Q1, reflecting a 10.8% year-over-year increase and surpassing market expectations by $26.96 million, demonstrating sustained growth in sales and market demand.
- Optimistic Outlook: Aptar anticipates adjusted EPS for Q2 2026 to be in the range of $1.32 to $1.40, reflecting confidence in future performance while assuming an effective tax rate between 22.5% and 24.5%.
- Exchange Rate Consideration: This earnings guidance is based on an exchange rate of 1.18 Euros to USD, highlighting the company's foreign exchange risk management strategy in its global operations.
See More
Aptar Named One of America's Climate Leaders for Fourth Consecutive Year
- Recognition as Climate Leader: AptarGroup has been named one of America's Climate Leaders by USA Today for the fourth consecutive year, reflecting the company's long-term commitment to sustainability and climate action, thereby enhancing its market reputation in environmental stewardship.
- Emission Reduction Achievements: Since its 2019 baseline year, Aptar has achieved significant reductions in Scope 1 and Scope 2 emissions, indicating effective measures in reducing climate impact and further solidifying its leadership position in the industry.
- Science-Based Targets: Aptar's science-based targets align with the goal of limiting global warming to 1.5°C, aiming for reductions in renewable electricity use and Scope 3 emissions by 2030, showcasing its proactive strategies in addressing climate change.
- Global Recognition and Engagement: Aptar has been recognized by CDP with an
See More
Aptar Partners with Enable for enFuse® Digital Health Solution
- Strategic Partnership: Aptar Digital Health has formed a strategic partnership with Enable Injections, becoming the preferred digital health partner for the enFuse® system, aimed at enhancing patient experience and engagement throughout the injection process.
- Digital Solution Features: The new solution will include features such as treatment data recording, onboarding modules, injection guidance, and symptom tracking, empowering patients and caregivers with greater confidence and control over the treatment process, thereby improving adherence.
- Flexible Architecture Design: Built on a flexible and scalable architecture, the solution will be deployed alongside the enFuse® system, supporting pharmaceutical partners across the entire drug development lifecycle from clinical trials to commercialization, enhancing the therapeutic value.
- Data-Driven Decision Making: By capturing adherence data and patient-reported outcomes remotely and providing actionable insights through analytics dashboards, the solution will assist pharmaceutical companies in making more informed decisions in clinical development and market readiness, ultimately improving the patient treatment journey.
See More
